Social Media

In a warning letter publicly posted on August 4, 2010, the FDA cited the “Facebook Share” functionality on Novartis’ Tasigna website for failing to deliver appropriate risk and efficacy information, and for failure to pre-clear the communications. This suggests that DDMAC considers “Facebook Share” and other content sharing technology –generated messages to be promotional material, and all stakeholders must fully understand and evaluate this functionality before including it on any branded or unbranded website.

RTCRM Perspectives – Facebook Share This Function Warning Letter

Comments are closed.

Our Background

Over 40 Years Experience

We have a long background in providing marketing services, with headquarters in Washington, DC and an office in New York City.

learn more

Our Practices

Strategy & Insights

We possess the unique ability to analyze data and research on both a rational and emotional level. This enables us to reveal subtle — often overlooked — customer insights and develop communications that truly change behavior.

learn more

Awards

Getting Recognized

Helping to drive client success is our top priority. But being recognized in the industry feels pretty good, too.

view our latest awards